Found 14 Acute Myeloid Leukemia trials
A listing of Acute Myeloid Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
UPCC 03722 A prospective randomized double-blind placebo-controlled multi-center phase IIb study to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)
The purpose of this study is to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
CART-38 in Adult AML and MM Patients
See protocol section 2 See protocol section 2 See protocol section 2
Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)
Phase 3
Pleae refer to Section 3 (Objectives and Endpoints) of the full protocol Please refer to Section 3.1 (Primary Endpoint) of the full protocol Please refer to Section 3.2 (Secondary Endpoints) of the full protocol
UPCC 42422: A Phase 1/2 Multicenter Open-Label Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible for Intensive Induction Chemotherapy
Gilteritinib, given with venetoclax and azacitidine, is a potential new treatment for people with acute myeloid leukemia with changed FLT3 gene where chemo is not an option due to old age/other conditions. Aims of this study: find suitable doses of gilteritinib, venetoclax and azacitidine as combined treatment; to learn how …
A Randomized Study Comparing Venetoclax and Azacitidine to Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia
Phase 2
This research is being done to see how an investigational combination of study drugs works in comparison to chemotherapy in people with acute myeloid leukemia. This study involves the following study drug combinations. You will only receive one of these combinations: • Venetoclax and azacitidine (investigational combination) • Cytarabine and …
UPCC 27423 V-RULES: Vyxeos Real-world US Long-term Effectiveness and Safety Study
This is a retrospective, non-interventional, multi-center, single-arm, observational study of patients with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) who have been treated with Vyxeos in real world clinical practice and managed as per the healthcare providers discretion. The study will collect pseudonymized patient …
AZA-MDS-006: Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification …
UPCC 25423 A Phase 1, Open-label, Dose-finding Study of CC-91633 (BMS-986397) in Subjects with Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Study CC-91633-AML-001 is a Phase 1, open-label, dose escalation and expansion, first-in-human (FIH) clinical study of CC-91633 (BMS-986397) in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). We would like to rely on WCG IRB as …
Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute Myeloid Leukemia (AMELI-01)
Phase 1
This study is evaluating the safety and efficacy of UCART targeting CD123 in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of UCART123v1.2 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
UPCC 09422: Specialty Compared to Oncology Delivered Palliative Care for Patients with Acute Myeloid Leukemia SCOPE-Leukemia
This study will randomly assign hospitals to deliver either specialty palliative care or primary palliative care for patients with AML. Our site will provide participants with specialty palliative care. This study will enroll patients, their caregivers, and key informants (health care clinician or leader) to provide perspectives on palliative care.
1 - 10 of 14
- 1
- 2
